Abstract
Background: Prolonged labour and operative delivery are more common among women with obesity, suggesting impaired myometrial contractility, although the underlying mechanisms remain unclear. Adipokines have been proposed as potential mediators in these processes due to their contractility inhibiting properties in vitro. The objective was to examine associations between maternal plasma leptin and visfatin concentrations during labour and labour outcomes related to impaired uterine contractility in women with obesity.Methods: In this prospective cohort study, 262 women with obesity (BMI ≥ 30) provided plasma samples during active labour. Participants were categorized into groups based on percentiles of maternal leptin and visfatin concentrations within the cohort (<25th, 25–<75th and ≥75th percentiles for each adipokine). Maternal and obstetric outcomes were compared across groups. Correlations with BMI were assessed, and associations with labour duration were evaluated using linear regression and Kaplan-Meier analyses.Findings: Leptin concentrations correlated positively with BMI (r = 0·300, p < 0·001), whereas visfatin did not (r = 0·094, p = 0·14). Prolonged active labour was more common among women with high leptin concentrations (p = 0·02). Higher leptin concentrations were independently associated with longer labour duration (+1·44 min/ng/mL, p = 0·03). Visfatin was not independently associated with longer labour duration. There was a possible lower probability for birth at a specific timepoint for women with concomitantly high leptin and visfatin levels, consistent with a potential additive effect (p 0·89 for difference across all groups).InterpretationAmong women with obesity, elevated maternal leptin during labour was associated with increasing BMI and longer labour duration, supporting a potential role in obesity-related labour dysfunction, whereas visfatin showed no independent associations.Funding: This research was supported by the Swedish Research Council for Health, Working Life and Welfare (FORTE) through the Centre Grant for Women’s Health (MAMA Research HUB) (MB), and research grants from Region Östergötland (SC), Medical Research Council of Southeast Sweden (SC), research grant from Region Kalmar County (ON). The funders had no part in the process of study design, writing, or publication.